New Roflumilast Cream Shows Promise for Infant Atopic Dermatitis Relief
Roflumilast cream sNDA targets infants with atopic dermatitis
Arcutis Biotherapeutics recently filed a supplemental new drug application (sNDA) seeking approval of roflumilast cream 0.05% for infants with atopic dermatitis (AD), based on data from a dedicated infant trial presented by Patrick Burnett, MD, PhD, the company’s chief medical officer. (Source: Arcutis Biotherapeutics press release, INTEGUMENT-INFANT trial)
What the INTEGUMENT-INFANT trial looked at
The application draws on results from the open-label INTEGUMENT-INFANT study, which evaluated safety and efficacy of the cream in infants aged 3 to 24 months with mild to moderate AD over a 4-week treatment period. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
Open-label means caregivers and clinicians knew the patients were receiving the active treatment rather than a placebo, a common approach when gathering initial safety and real-world tolerability data in very young children. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
The trial enrolled 101 infants and collected caregiver-reported outcomes, clinician assessments, and safety monitoring to build a comprehensive picture of how the cream performs in this sensitive age group. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
Safety findings in infants
Overall, the safety profile observed in infants matched what had been seen in older pediatric populations, with no new or unexpected safety signals reported. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
The most commonly reported adverse events included diarrhea, nasopharyngitis, upper respiratory tract infection (URTI), and infrequent vomiting—events the investigators noted are typical in this age range and not necessarily linked to the topical therapy. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
Importantly, investigators concluded the cream was generally well tolerated in infants aged 3 months and older, supporting its safety for use in very young patients when supervised by clinicians. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
Efficacy: meaningful skin improvements over four weeks
The INTEGUMENT-INFANT results showed clinically relevant improvements by week 4 on several commonly used measures in eczema trials. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
About one-third of patients achieved Investigator’s Global Assessment (IGA) success, defined here as skin rated clear or almost clear plus at least a two-grade improvement from baseline—an important benchmark clinicians use to judge meaningful change. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
Another widely used endpoint, EASI-75 (a 75% improvement on the Eczema Area and Severity Index), was reached by 58% of participants by week 4—suggesting robust reduction in disease severity for a majority of infants over the short study period. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
Scalp disease and itch relief
The trial paid special attention to scalp involvement, a feature often missed in infant AD, and found that 67.5% of infants with scalp disease achieved scalp-specific success—highlighting the cream’s activity in a frequently problematic area. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
Rapid improvement in itching was also reported: nearly half of patients experienced at least a 25% reduction in pruritus within 10 minutes of the first application, based on caregiver reports—an outcome that can be especially meaningful for infants and families coping with sleep disruption and distress. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
Formulation matters for infants’ sensitive skin
Burnett emphasized formulation details that are particularly relevant for infants, noting that the once-daily 0.05% cream is free of common irritating excipients such as fragrances, propylene glycol, and ethanol. (Source: Arcutis Biotherapeutics press release, INTEGUMENT-INFANT trial)
Removing these ingredients aligns with standard counseling for infant AD, where minimizing potential irritants and sensitizers is a routine part of care for developing, sensitive skin. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
Practical advantages and caregiver concerns
The product’s once-daily dosing was highlighted as a practical benefit for families managing chronic disease, simplifying routines and potentially improving adherence. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
Because the cream is a nonsteroidal anti-inflammatory option, the therapy may help address “steroid phobia” among caregivers who worry about long-term topical corticosteroid use, offering an alternative for maintenance or repeated use under medical guidance. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
Expert perspective and the pediatric landscape
Burnett reminded readers that treating infants involves unique considerations: the immune system and the skin barrier are both maturing in the first months of life, which makes this group especially sensitive to treatments and environmental exposures. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
He also pointed to a broader trend of increased pediatric drug development in dermatology, with more companies pursuing studies for inflammatory skin diseases that historically lacked age-appropriate options. (Source: Arcutis Biotherapeutics press release)
Despite progress, Burnett noted unmet needs remain across pediatric dermatology—using acne as an example of a common condition in younger patients where better, age-appropriate therapies are still required. (Source: Arcutis Biotherapeutics press release)
What this could mean for families and clinicians
If approved, once-daily roflumilast cream 0.05% would add a nonsteroidal, preservative- and fragrance-free topical option for infants with mild to moderate AD, backed by early safety and efficacy data from a purpose-designed infant study. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
Clinicians will still weigh individual patient needs, severity, and prior treatment response, but having a therapy that demonstrated both rapid itch relief and meaningful reductions in disease severity in infants could change how some providers and families approach early treatment and long-term disease management. (Source: Arcutis Biotherapeutics press release)
Conclusion
The INTEGUMENT-INFANT findings provide a focused dataset supporting Arcutis’s sNDA for roflumilast cream in infants, showing a tolerability profile consistent with older children and promising efficacy signals across several endpoints, including itch and scalp disease. (Source: Arcutis Biotherapeutics, INTEGUMENT-INFANT trial)
As pediatric dermatology research expands, these kinds of studies help fill gaps in age-appropriate care—but they also underscore the ongoing need for new treatments across childhood conditions like acne and other inflammatory disorders. (Source: Arcutis Biotherapeutics press release)
Sources
- Arcutis Biotherapeutics press release and investigator presentation, INTEGUMENT-INFANT trial (data and sNDA submission)
- INTEGUMENT-INFANT trial clinical data summary (Arcutis Biotherapeutics, study report)
- ClinicalTrials.gov, INTEGUMENT-INFANT study listing (trial registration and design summary)